Merck (MRK) EPS (Weighted Average and Diluted) (2009 - 2026)
Merck (MRK) reported EPS (Weighted Average and Diluted) of -$1.72 for Q1 2026, down 185.57% year-over-year from $2.01 in Q1 2025, and down 243.33% on a QoQ basis from $1.2 in Q4 2025.
Merck (MRK) has 18 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.72 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) fell 185.57% year-over-year to -$1.72 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.56 (down 48.18% YoY) and the FY2025 annual result came in at $7.28, up 8.01% from the prior year.
- EPS (Weighted Average and Diluted) fell to -$1.72 in Q1 2026 per MRK's latest filing, from $1.2 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $2.32 in Q3 2025 and bottomed at -$2.35 in Q2 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is $1.48 (2024), against an average of $1.07.
- The widest annual swing landed in 2023, when EPS (Weighted Average and Diluted) slumped 251.61%; it then jumped 408.33% in 2024.
- Tracing MRK's EPS (Weighted Average and Diluted) over 5 years: stood at $1.18 in 2022, then slumped by 140.68% to -$0.48 in 2023, then jumped by 408.33% to $1.48 in 2024, then slipped by 18.92% to $1.2 in 2025, then slumped by 243.33% to -$1.72 in 2026.
- Per Business Quant, the three latest MRK EPS (Weighted Average and Diluted) figures stand at -$1.72 (Q1 2026), $1.2 (Q4 2025), and $2.32 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 8.26 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 0.39 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -1.72 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 3.34 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.61 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.47 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 1.31 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.72 |
| Dec 31, 2025 | 1.20 |
| Sep 30, 2025 | 2.32 |
| Jun 30, 2025 | 1.76 |
| Mar 31, 2025 | 2.01 |
| Dec 31, 2024 | 1.48 |
| Sep 30, 2024 | 1.24 |
| Jun 30, 2024 | 2.14 |
| Mar 31, 2024 | 1.87 |
| Dec 31, 2023 | -0.48 |
| Sep 30, 2023 | 1.86 |
| Jun 30, 2023 | -2.35 |
| Mar 31, 2023 | 1.11 |
| Dec 31, 2022 | 1.18 |
| Sep 30, 2022 | 1.28 |
| Jun 30, 2022 | 1.55 |
| Mar 31, 2022 | 1.70 |
| Dec 31, 2021 | 1.20 |
| Sep 30, 2021 | 1.80 |
| Jun 30, 2021 | 0.61 |
| Mar 31, 2021 | 1.08 |
| Dec 31, 2020 | -0.83 |
| Sep 30, 2020 | 1.16 |
| Jun 30, 2020 | 0.92 |
| Mar 31, 2020 | 1.26 |
| Dec 31, 2019 | 0.92 |
| Sep 30, 2019 | 0.74 |
| Jun 30, 2019 | 1.03 |
| Mar 31, 2019 | 1.12 |
| Dec 31, 2018 | 0.69 |
| Sep 30, 2018 | 0.73 |
| Jun 30, 2018 | 0.63 |
| Mar 31, 2018 | 0.27 |
| Dec 31, 2017 | -0.38 |
| Sep 30, 2017 | -0.02 |
| Jun 30, 2017 | 0.71 |
| Mar 31, 2017 | 0.56 |
| Dec 31, 2016 | -0.21 |
| Sep 30, 2016 | 0.78 |
| Jun 30, 2016 | 0.43 |
| Mar 31, 2016 | 0.40 |
| Dec 31, 2015 | 0.34 |
| Sep 30, 2015 | 0.64 |
| Jun 30, 2015 | 0.24 |
| Mar 31, 2015 | 0.33 |
| Dec 31, 2014 | 2.50 |
| Sep 30, 2014 | 0.31 |
| Jun 30, 2014 | 0.68 |
| Mar 31, 2014 | 0.57 |
| Dec 31, 2013 | 0.27 |
| Sep 30, 2013 | 0.38 |
| Jun 30, 2013 | 0.30 |
| Mar 31, 2013 | 0.52 |
| Dec 31, 2012 | 0.29 |
| Sep 30, 2012 | 0.56 |
| Jun 30, 2012 | 0.58 |
| Mar 31, 2012 | 0.56 |
| Dec 31, 2011 | 0.49 |
| Sep 30, 2011 | 0.55 |
| Jun 30, 2011 | 0.65 |
| Mar 31, 2011 | 0.34 |
| Dec 31, 2010 | -0.16 |
| Sep 30, 2010 | 0.11 |
| Jun 30, 2010 | 0.24 |
| Mar 31, 2010 | 0.09 |
| Dec 31, 2009 | 2.62 |
| Sep 30, 2009 | 1.61 |
| Jun 30, 2009 | 0.74 |
| Mar 31, 2009 | 0.67 |